{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:54:32Z","timestamp":1794639272781,"version":"4.9.1"},"reference-count":65,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The ongoing development of immunotherapies, including chimeric antigen receptor (CAR) T cells, has revolutionized cancer treatment. In pediatric relapsed\/refractory B-lineage acute leukemia antiCD19-CAR induce impressive initial response rates, with event-free survival plateauing at 30-50% according to long-term follow-up data. During the interval between diagnosis of relapse or refractoriness and CAR T-cell infusion, patients require a bridging therapy. To date, this therapy has consisted of highly variable approaches based on local experience. Here, in an European collaborative effort of pediatric and adult hematologists, we summarize current knowledge with the aim of establishing guidance for bridging therapy. We discuss treatment strategies for different subgroups of patients, the advantages and disadvantages of low- and high-intensity regimens, and the potential impact of bridging therapy on outcomes after CAR T-cell infusion. This guidance is a step towards cross-institutional harmonization of bridging therapy, including personalized approaches. This will allow better comparability of clinical data and increase the level of evidence for the treatment of children and young adults with relapsed\/ refractory B-lineage acute leukemia until they can receive CAR T-cell infusion.<\/jats:p>","DOI":"10.3324\/haematol.2023.283780","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:27:05Z","timestamp":1707967625000},"page":"3892-3903","source":"Crossref","is-referenced-by-count":8,"title":["Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic B-lineage leukemia in children and young adults"],"prefix":"10.3324","volume":"109","author":[{"given":"Tobias","family":"Feuchtinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Breidenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semjon","family":"Willier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Gerhardt","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fr\u00fchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Troeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"K\u00fcnkele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Von Stackelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"69495","doi-asserted-by":"crossref","unstructured":"Sun W, Malvar J, Sposto R. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia &amp; Lymphoma study. Leukemia. 2018; 32(11):2316-2325.","DOI":"10.1038\/s41375-018-0094-0"},{"key":"69496","doi-asserted-by":"crossref","unstructured":"Sadelain M. CD19 CAR T cells. Cell. 2017; 171(7):1471.","DOI":"10.1016\/j.cell.2017.12.002"},{"key":"69497","doi-asserted-by":"crossref","unstructured":"Maude SL, Frey N, Shaw PA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-1517.","DOI":"10.1056\/NEJMoa1407222"},{"key":"69498","doi-asserted-by":"crossref","unstructured":"Brentjens RJ, Davila ML, Riviere I. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra138.","DOI":"10.1126\/scitranslmed.3005930"},{"key":"69499","doi-asserted-by":"crossref","unstructured":"Laetsch TW, Maude SL, Rives S. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023; 41(9):1664-1669.","DOI":"10.1200\/JCO.22.00642"},{"key":"69500","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5):439-448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"69501","doi-asserted-by":"crossref","unstructured":"Park JH, Riviere I, Gonen M. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018; 378(5):449-459.","DOI":"10.1056\/NEJMoa1709919"},{"key":"69502","doi-asserted-by":"crossref","unstructured":"Shah BD, Ghobadi A, Oluwole OO. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502.","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"69503","doi-asserted-by":"crossref","unstructured":"Shahid S, Ramaswamy K, Flynn J. Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia. Transplant Cell Ther. 2022; 28(2):72.","DOI":"10.1016\/j.jtct.2021.11.014"},{"key":"69504","doi-asserted-by":"crossref","unstructured":"Ghorashian S, Jacoby E, De Moerloose B. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. Lancet Haematol. 2022; 9(10):e766-e775.","DOI":"10.1016\/S2352-3026(22)00225-3"},{"key":"69505","doi-asserted-by":"crossref","unstructured":"Myers RM, Taraseviciute A, Steinberg SM. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022; 40(9):932-944.","DOI":"10.1200\/JCO.21.01405"},{"key":"69506","doi-asserted-by":"crossref","unstructured":"Schultz LM, Baggott C, Prabhu S. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium report. J Clin Oncol. 2022; 40(9):945-955.","DOI":"10.1200\/JCO.20.03585"},{"key":"69507","doi-asserted-by":"crossref","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517-528.","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"69508","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi LA, Berger C. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016; 126(6):2123-2138.","DOI":"10.1172\/JCI85309"},{"key":"69509","doi-asserted-by":"crossref","unstructured":"Perica K, Flynn J, Curran KJ. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 2021; 35(11):3268-3271.","DOI":"10.1038\/s41375-021-01196-3"},{"key":"69510","doi-asserted-by":"crossref","unstructured":"Pinnix CC, Gunther JR, Dabaja BS. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020; 4(13):2871-2883.","DOI":"10.1182\/bloodadvances.2020001837"},{"key":"69511","doi-asserted-by":"crossref","unstructured":"Bader P, Kreyenberg H, Henze GH. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009; 27(3):377-384.","DOI":"10.1200\/JCO.2008.17.6065"},{"key":"69512","doi-asserted-by":"crossref","unstructured":"Peters C, Dalle JH, Locatelli F. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021; 39(4):295-307.","DOI":"10.1200\/JCO.20.02529"},{"key":"69513","doi-asserted-by":"crossref","unstructured":"Dourthe ME, Rabian F, Yakouben K. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021; 35(12):3383-3393.","DOI":"10.1038\/s41375-021-01281-7"},{"key":"69514","doi-asserted-by":"crossref","unstructured":"Ghassemi S, Durgin JS, Nunez-Cruz S. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng. 2022; 6(2):118-128.","DOI":"10.1038\/s41551-021-00842-6"},{"key":"69515","doi-asserted-by":"crossref","unstructured":"Blache U, Popp G, Dunkel A, Koehl U, Fricke S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat Commun. 2022; 13(1):5225.","DOI":"10.1038\/s41467-022-32866-0"},{"key":"69516","doi-asserted-by":"crossref","unstructured":"Das RK, Vernau L, Grupp SA, Barrett DM. Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019; 9(4):492-499.","DOI":"10.1158\/2159-8290.CD-18-1314"},{"key":"69517","doi-asserted-by":"crossref","unstructured":"Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016; 8(320):320ra3.","DOI":"10.1126\/scitranslmed.aad5222"},{"key":"69518","doi-asserted-by":"crossref","unstructured":"Ruella M, Xu J, Barrett DM. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503.","DOI":"10.1038\/s41591-018-0201-9"},{"key":"69519","doi-asserted-by":"crossref","unstructured":"Ceppi F, Rivers J, Annesley C. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion. 2018; 58(6):1414-1420.","DOI":"10.1111\/trf.14569"},{"key":"69520","doi-asserted-by":"crossref","unstructured":"Allen ES, Stroncek DF, Ren J. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion. 2017; 57(5):1133-1141.","DOI":"10.1111\/trf.14003"},{"key":"69521","doi-asserted-by":"crossref","unstructured":"Myers RM, Shah NN, Pulsipher MA. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL. Blood. 2023; 141(11):1251-1264.","DOI":"10.1182\/blood.2022016937"},{"key":"69522","doi-asserted-by":"crossref","unstructured":"Kansagra AJ, Frey NV, Bar M. Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019; 54(11):1868-1880.","DOI":"10.1038\/s41409-019-0451-2"},{"key":"69523","doi-asserted-by":"crossref","unstructured":"Del Bufalo F, Becilli M, Rosignoli C. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood. 2023; 142(2):146-157.","DOI":"10.1182\/blood.2023020023"},{"key":"69524","doi-asserted-by":"crossref","unstructured":"Chen S, Zhang Y, Fang C. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R\/R ALL and NHL: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022; 179:103807.","DOI":"10.1016\/j.critrevonc.2022.103807"},{"key":"69525","doi-asserted-by":"crossref","unstructured":"Bonini C, Chapuis AG, Hudecek M. Genome editing in engineered T cells for cancer immunotherapy. Hum Gene Ther. 2023; 34(17-18):853-869.","DOI":"10.1089\/hum.2023.128"},{"key":"69526","doi-asserted-by":"crossref","unstructured":"Benjamin R, Graham C, Yallop D. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020; 396(10266):1885-1894.","DOI":"10.1016\/S0140-6736(20)32334-5"},{"key":"69527","unstructured":"Rives S. Tisagenlecleucel in pediatric and young adult patients (Pts) with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study. Oral presentation at: 2022 Hybrid Congress of the European Hematology Association (EHA). 2022."},{"key":"69528","doi-asserted-by":"crossref","unstructured":"Jabbour E, Short NJ, Jain N. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023; 16(1):22.","DOI":"10.1186\/s13045-023-01409-5"},{"key":"69529","doi-asserted-by":"crossref","unstructured":"Bader P, Rossig C, Hutter M. CD19-CAR-T cells are an effective therapy of post-transplant relapse in B-ALL patients: real-world data from Germany. Blood Adv. 2023; 7(11):2436-2448.","DOI":"10.1182\/bloodadvances.2022008981"},{"key":"69530","doi-asserted-by":"crossref","unstructured":"Mahadeo KM, Khazal SJ, Abdel-Azim H. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019; 16(1):45-63.","DOI":"10.1038\/s41571-018-0075-2"},{"key":"69531","doi-asserted-by":"crossref","unstructured":"Khan I, Khan N, Wolfson N. Safety of CAR-T cell therapy in patients with renal failure\/acute kidney injury: focused review. Clin Hematol Int. 2023; 5(2-3):122-129.","DOI":"10.1007\/s44228-023-00037-7"},{"key":"69532","doi-asserted-by":"crossref","unstructured":"Niu J, Qiu H, Xiang F. CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer J. 2023; 13(1):44.","DOI":"10.1038\/s41408-023-00813-x"},{"key":"69533","doi-asserted-by":"crossref","unstructured":"Hu GH, Cheng YF, Zuo YX. Chimeric antigens receptor T cell therapy improve the prognosis of pediatric acute lymphoblastic leukemia with persistent\/recurrent minimal residual disease in first complete remission. Front Immunol. 2021; 12:731435.","DOI":"10.3389\/fimmu.2021.731435"},{"key":"69534","doi-asserted-by":"crossref","unstructured":"Schultz LM, Eaton A, Baggott C. Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia. J Clin Oncol. 2023; 41(2):354-363.","DOI":"10.1200\/JCO.22.01076"},{"key":"69535","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; 375(8):740-753.","DOI":"10.1056\/NEJMoa1509277"},{"key":"69536","doi-asserted-by":"crossref","unstructured":"Bhojwani D, Sposto R, Shah NN. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019; 33(4):884-892.","DOI":"10.1038\/s41375-018-0265-z"},{"key":"69537","doi-asserted-by":"crossref","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021; 137(12):1582-1590.","DOI":"10.1182\/blood.2020007848"},{"key":"69538","doi-asserted-by":"crossref","unstructured":"O\u2019Brien MM, Ji L, Shah NN. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group protocol AALL1621. J Clin Oncol. 2022; 40(9):956-967.","DOI":"10.1200\/JCO.21.01693"},{"key":"69539","doi-asserted-by":"crossref","unstructured":"Ceolin V, Brivio E, van Tinteren H. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 2023; 37(1):53-60.","DOI":"10.1038\/s41375-022-01740-9"},{"key":"69540","doi-asserted-by":"crossref","unstructured":"Wullenkord R, Reicherts C, Mikesch JH. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia. Ann Hematol. 2021; 100(2):587-589.","DOI":"10.1007\/s00277-020-04227-8"},{"key":"69541","doi-asserted-by":"crossref","unstructured":"Rubinstein JD, Breese EH, Krupski MC. The choice of either conventional chemotherapy or inotuzumab ozogamicin as bridging regimen does not appear to impact clinical response to CD19-directed CAR-T therapy in pediatric B-ALL. Transplant Cell Ther. 2023; 29(5):311.","DOI":"10.1016\/j.jtct.2023.02.012"},{"key":"69542","doi-asserted-by":"crossref","unstructured":"Jacoby E, Ghorashian S, Vormoor B. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. 2022; 36(6):1525-1532.","DOI":"10.1038\/s41375-022-01546-9"},{"key":"69543","doi-asserted-by":"crossref","unstructured":"Leahy AB, Newman H, Li Y. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021; 8(10):e711-e722.","DOI":"10.1016\/S2352-3026(21)00238-6"},{"key":"69544","doi-asserted-by":"crossref","unstructured":"Salzer WL, Burke MJ, Devidas M. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: Children\u2019s Oncology Group study AALL1131. J Clin Oncol. 2020; 38(23):2628-2638.","DOI":"10.1200\/JCO.19.02892"},{"key":"69545","doi-asserted-by":"crossref","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021; 11(6):1440-1453.","DOI":"10.1158\/2159-8290.CD-20-1465"},{"key":"69546","doi-asserted-by":"crossref","unstructured":"Ottmann O, Dombret H, Martinelli G. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110(7):2309-2315.","DOI":"10.1182\/blood-2007-02-073528"},{"key":"69547","doi-asserted-by":"crossref","unstructured":"Ottmann OG, Larson RA, Kantarjian HM. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. Leukemia. 2013; 27(6):1411-1413.","DOI":"10.1038\/leu.2012.324"},{"key":"69548","doi-asserted-by":"crossref","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369(19):1783-1796.","DOI":"10.1056\/NEJMoa1306494"},{"key":"69549","doi-asserted-by":"crossref","unstructured":"Leclercq G, Haegel H, Schneider A. Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. J Immunother Cancer. 2021; 9(7):e002582.","DOI":"10.1136\/jitc-2021-002582"},{"key":"69550","doi-asserted-by":"crossref","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022; 40(1):26-35.","DOI":"10.1016\/j.ccell.2021.12.004"},{"key":"69551","doi-asserted-by":"crossref","unstructured":"Talleur AC, Qudeimat A, Metais JY. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Adv. 2022; 6(21):5737-5749.","DOI":"10.1182\/bloodadvances.2021006293"},{"key":"69552","doi-asserted-by":"crossref","unstructured":"DeAngelo DJ, Advani AS, Marks DI. Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020; 10(8):81.","DOI":"10.1038\/s41408-020-00345-8"},{"key":"69553","doi-asserted-by":"crossref","unstructured":"Bader P, Kreyenberg H, Ossenkoppele G. Monitoring minimal residual disease in ALL and AML. 2019;431-436.","DOI":"10.1007\/978-3-030-02278-5_57"},{"key":"69554","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE; version 5.0; published November 27, 2017)."},{"key":"69555","doi-asserted-by":"crossref","unstructured":"Lee DW, Gardner R, Porter DL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"69556","doi-asserted-by":"crossref","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127(26):3321-3330.","DOI":"10.1182\/blood-2016-04-703751"},{"key":"69557","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"69558","doi-asserted-by":"crossref","unstructured":"Brown BD, Tambaro FP, Kohorst M. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis?. Front Oncol. 2021; 11:634445.","DOI":"10.3389\/fonc.2021.634445"},{"key":"69559","doi-asserted-by":"crossref","unstructured":"Mahdi J, Dietrich J, Straathof K. Tumor inflammation-associated neurotoxicity. Nat Med. 2023; 29(4):803-810.","DOI":"10.1038\/s41591-023-02276-w"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283780\/76615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283780\/77828","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11444\/76615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:45Z","timestamp":1794045945000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283780","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}